Brief: Mesoblast Ltd Says FY Loss Attributable $81.9 Mln
31/08/2023 02:33
Aug 31 (Reuters) - Mesoblast Ltd MSB.AX :
* FY LOSS ATTRIBUTABLE $81.9 MILLION VERSUS LOSS $91.3 MN
Source text for Eikon: ID:nASX1lS1FF
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast William Burns To Retire From Board At 2026 AGM
Brief: Mesoblast Says Q1 Net Revenues Up 44%
Australia's Mesoblast hits one-month high on upbeat quarterly update
Australia's Mesoblast drops as Bell Potter cuts target price after key drug misses sales view
Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil